Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Ups R&D Spend Amid Avelumab Anticipation

This article was originally published in Scrip

Executive Summary

Merck of Germany's R&D spend in immuno-oncology will be €150–200m higher in 2016 than in 2015, it said at its Capital Market Day (Dec. 10). Much of this will be allocated to the antibody avelumab, which Merck is co-developing with Pfizer, as well as to projects in early stages of clinical development. In total, Merck is planning additional investments of around €250m in its pharmaceutical pipeline.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC063935

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel